When Will Melanoma Vaccines Be Proven Effective?
- 1 February 2004
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (3) , 387-389
- https://doi.org/10.1200/jco.2004.11.950
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Immunopharmacologic Analysis of an Autologous, Hapten-Modified Human Melanoma VaccineJournal of Clinical Oncology, 2004
- Current Developments in Cancer Vaccines and Cellular ImmunotherapyJournal of Clinical Oncology, 2003
- Medical management of melanomaSurgical Clinics of North America, 2003
- A Controlled Trial of a Human Papillomavirus Type 16 VaccineNew England Journal of Medicine, 2002
- Risk Assessment in Localized Primary Cutaneous MelanomaAmerican Journal of Clinical Pathology, 2002
- Disease-associated Bias in T Helper Type 1 (Th1)/Th2 CD4+ T Cell Responses Against MAGE-6 in HLA-DRB10401+ Patients With Renal Cell Carcinoma or MelanomaThe Journal of Experimental Medicine, 2002
- Wnt5a signaling directly affects cell motility and invasion of metastatic melanomaCancer Cell, 2002
- Universal Hepatitis B Vaccination in Taiwan and the Incidence of Hepatocellular Carcinoma in ChildrenNew England Journal of Medicine, 1997
- Dendritic Cells in Antitumor Immune ResponsesCellular Immunology, 1996
- Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.Proceedings of the National Academy of Sciences, 1994